https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51433 Wed 22 May 2024 15:28:13 AEST ]]> Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45667 Wed 02 Nov 2022 15:59:08 AEDT ]]> Prediction of multiple sclerosis outcomes when switching to ocrelizumab https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46515 Thu 24 Nov 2022 15:50:23 AEDT ]]> Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52624 Thu 19 Oct 2023 14:15:33 AEDT ]]> Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48108 Mon 27 Feb 2023 15:18:00 AEDT ]]> Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51965 Mon 25 Sep 2023 08:53:21 AEST ]]> Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51882 Fri 22 Sep 2023 09:08:11 AEST ]]> Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53317 Fri 19 Jan 2024 14:25:45 AEDT ]]>